Wow, okay, I have to admit, financial stuff usually makes my eyes glaze over faster than you can say “stock market,” but something about this Omada Health thing piqued my interest. And yes, I’m aware how cliché that sounds. Anyway, for whatever reason, Goldman Sachs is rooting for this newly public virtual care company like it’s some underdog sports team, which, who knew financial analysts had teams? Apparently, this dude David Roman thinks Omada’s stock is gonna shoot up like 58.5%, which, uh, is a lot? I mean, apparently it just hit the Nasdaq mid-last year, so there’s that whole new kid on the block vibe too.
So, Roman, in his very official note—probably scribbled on a Starbucks napkin, but I digress—mentions “OMDA” like it’s the code name for a secret mission instead of a stock ticker. He’s convinced this company’s gonna be the next big thing, especially since they’re working on virtual support for chronic conditions. I guess it’s like having a doctor in your pocket except not literally… unless your doctor is teeny tiny. Okay, maybe not the best metaphor.
Here’s the thing though: there are a ton of folks in the U.S. with chronic conditions. Something like 156 million, which is a number I can’t really wrap my head around. But Roman is throwing out that number like it’s a baseball stat. Apparently, the whole chronic conditions gig costs the U.S. a cool trillion bucks a year. That’s a lot of zeroes, people.
And, Omada? Well, they’ve been bragging about a revenue jump—like from $35.1 million to $55 million in just the first quarter, which, I mean, sounds impressive. Their total revenue was nearly $170 million in 2024. If I made that much, I’d be sitting on a beach somewhere, probably laughing at this article I wrote years before. Also, the stock price was initially $19, and now it’s a bit lower. Maybe it’s like that moment when you first jump into a cold pool and have second thoughts. Who knows.
Plus, they’ve got this thing with EncircleRx and CVS, and something called a GLP-1 program? Not sure what that is, to be honest. But it must be important since Roman’s betting on it driving growth. Somehow, it feels like Omada’s got this secret sauce for growth, and investors are just waiting to swipe the recipe.
Enough rambling—guess we’ll just have to wait and see if Roman’s onto something or just dreaming of a big payday.
